Page last updated: 2024-12-10

tauropine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tauropine: RN given from CA Index Guide 1985; RN not in Chemline 12/86 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tauropine : A derivative of L-alanine having a 2-sulfoethyl group attached to the alpha-nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3082376
CHEBI ID16461
SCHEMBL ID3713939
MeSH IDM0144294

Synonyms (15)

Synonym
rhodoic acid
d-alanine, n-(2-sulfoethyl)-
CHEBI:16461
n-(2-sulfoethyl)-d-alanine
n-(1-carboxyethyl)taurine
n(2)-(d-1-carboxyethyl)-2-aminoethanesulfonate
C01616
tauropine
33497-79-9
n2-(d-1-carboxyethyl)taurine
SCHEMBL3713939
n-(2-sulfoethyl)alanine
Q27101919
DTXSID60955123
(2r)-2-[(2-sulfoethyl)amino]propanoic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In conclusion, oral ingested tauropine may be poorly absorbed by the gastrointestinal tract and transported into the blood."( Bioavailability of Tauropine After Oral Ingestion in Mouse.
Hamano, Y; Ito, T; Maruyama, C; Murakami, S; Nguyen, KH; Schaffer, SW, 2022
)
1.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
D-alanine derivativeA non-proteinogenic amino acid derivative resulting from reaction of D-alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of D-alanine by a heteroatom.
D-alpha-amino acid
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]